ClinicalTrials.gg
RecruitingNCT05809284CARPERSUpdated Aug 7, 2026

Determining the Mechanisms of Loss of CAR T Cell Persistence

An observational study in Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission and Acute Lymphoblastic Leukemia, Pediatric, sponsored by University College, London. Recruiting at 3 sites in United Kingdom. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom — 17 open to participants now, 21 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United Kingdom.

Planned enrollment
9th of 13
50 · median 178
Started
2023
with 7 others
Observational
13 of 97
1 open now
Primary completion
2027-07
later than 6 of 20 live
Registered
85th of 97
by date
Lead sponsor
7 of 97
University College, London

Among the 97 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2023, is one of 13 observational ones, reaches primary completion later than 6 of the 20 other live ones, and was the 85th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

17 of the 97 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, or all of them as a file.
02

Study summary

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

03

Conditions studied

  • Acute Lymphoblastic Leukemia With Failed Remission
  • Acute Lymphoblastic Leukemia Not Having Achieved Remission
  • Acute Lymphoblastic Leukemia, Pediatric
  • Acute Lymphoblastic Leukemia, Adult
  • Acute Lymphoblastic Leukemia, in Relapse
04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is paediatric and young adult patients aged 25 or younger who have relapsed/refractory B-cell acute lymphoblastic leukaemia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children and young adults (age 25 years or younger) with ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
  2. Written

Exclusion criteria

Exclusion Criteria:

  1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
  2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Time to circulating CAR-T cell loss

    CAR-T persistence will be measured in the central lab from blood samples.

    Time frame: Through study completion, until the last patient reaches 1 year post-infusion

07

Study locations

3 of 3 sites recruiting
  • Great Ormond Street Hospital
    London, United Kingdom
    Recruiting
    • Persis Amrolia · Contact
    • Persis Amrolia · Principal investigator
  • University College London Hospital
    London, United Kingdom
    Recruiting
    • Rachael Hough · Contact
    • Rachael Hough · Principal investigator
  • Royal Manchester Children's Hospital
    Manchester, United Kingdom
    Recruiting
    • Denise Bonney · Contact
    • Denise Bonney · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 44 months is below that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Apr 12, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05809284
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Oct 18, 2023
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

CARPERS Trial Manager
Contact
ctc.carpers@ucl.ac.uk
442031084189
Persis Amrolia, BSc,MBBS,PhD
study chair · UCL Institute of Child Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion